Latest Insider Transactions at Exact Sciences Corp (EXAS)
This section provides a real-time view of insider transactions for Exact Sciences Corp (EXAS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of EXACT SCIENCES CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of EXACT SCIENCES CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 27
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
6,263
-0.48%
|
$350,728
$56.89 P/Share
|
|
Feb 27
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,710
-25.18%
|
$151,760
$56.89 P/Share
|
|
Feb 27
2024
|
Everett Cunningham Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,648
-7.77%
|
$204,288
$56.89 P/Share
|
|
Feb 27
2024
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
784
-8.83%
|
$43,904
$56.89 P/Share
|
|
Feb 27
2024
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
1,879
-13.78%
|
$105,224
$56.89 P/Share
|
|
Feb 26
2024
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+22.37%
|
-
|
|
Feb 26
2024
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+4.97%
|
-
|
|
Feb 26
2024
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
13,181
+1.01%
|
-
|
|
Feb 26
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,701
+34.63%
|
-
|
|
Feb 26
2024
|
Everett Cunningham Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,678
+14.06%
|
-
|
|
Feb 26
2024
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
1,648
+15.65%
|
-
|
|
Feb 26
2024
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
3,954
+22.48%
|
-
|
|
Feb 23
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,021
-1.4%
|
$60,239
$59.72 P/Share
|
|
Feb 23
2024
|
Kevin T Conroy President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
61,560
-4.58%
|
$3,508,920
$57.53 P/Share
|
|
Feb 23
2024
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
102,837
+7.11%
|
$1,336,881
$13.96 P/Share
|
|
Feb 22
2024
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
663
-1.47%
|
$39,117
$59.78 P/Share
|
|
Feb 22
2024
|
Everett Cunningham Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,350
-3.32%
|
$79,650
$59.78 P/Share
|
|
Feb 22
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,351
-21.06%
|
$79,709
$59.78 P/Share
|
|
Feb 22
2024
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
291
-3.87%
|
$17,169
$59.78 P/Share
|
|
Feb 22
2024
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
1,013
-9.47%
|
$59,767
$59.78 P/Share
|
|
Feb 22
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
1,093
-10.06%
|
$64,487
$59.78 P/Share
|
|
Feb 22
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,013
-1.37%
|
$59,767
$59.78 P/Share
|
|
Feb 22
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
11,565
-0.92%
|
$682,335
$59.78 P/Share
|
|
Feb 21
2024
|
D Scott Coward |
BUY
Grant, award, or other acquisition
|
Direct |
2,034
+4.31%
|
-
|
|
Feb 21
2024
|
Everett Cunningham Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,711
+6.26%
|
-
|
|
Feb 21
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,711
+29.71%
|
-
|
|
Feb 21
2024
|
James Herriott SVP, General Counsel & Sec |
BUY
Grant, award, or other acquisition
|
Direct |
581
+7.17%
|
-
|
|
Feb 21
2024
|
Jacob A Orville EVP, GM, Screening |
BUY
Grant, award, or other acquisition
|
Direct |
2,034
+15.98%
|
-
|
|
Feb 21
2024
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
2,034
+15.77%
|
-
|
|
Feb 21
2024
|
Sarah Condella EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
2,034
+2.69%
|
-
|
|
Feb 21
2024
|
Kevin T Conroy President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,238
+1.82%
|
-
|
|
Feb 21
2024
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
415
-5.64%
|
$25,315
$61.5 P/Share
|
|
Feb 21
2024
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
1,078
-11.07%
|
$65,758
$61.5 P/Share
|
|
Feb 21
2024
|
Brian Baranick EVP, GM, Precision Oncology |
SELL
Open market or private sale
|
Direct |
895
-9.21%
|
$54,595
$61.5 P/Share
|
|
Feb 21
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,079
-1.48%
|
$65,819
$61.5 P/Share
|
|
Feb 21
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
4,975
-0.4%
|
$303,475
$61.5 P/Share
|
|
Feb 21
2024
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
706
-1.61%
|
$43,066
$61.5 P/Share
|
|
Feb 21
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,493
-28.73%
|
$91,073
$61.5 P/Share
|
|
Feb 20
2024
|
James Herriott SVP, General Counsel & Sec |
BUY
Exercise of conversion of derivative security
|
Direct |
864
+10.51%
|
-
|
|
Feb 20
2024
|
Jacob A Orville EVP, GM, Screening |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+18.76%
|
-
|
|
Feb 20
2024
|
Brian Baranick EVP, GM, Precision Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,729
+15.1%
|
-
|
|
Feb 20
2024
|
Sarah Condella EVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+3.0%
|
-
|
|
Feb 20
2024
|
Kevin T Conroy President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,374
+0.83%
|
-
|
|
Feb 20
2024
|
D Scott Coward |
BUY
Exercise of conversion of derivative security
|
Direct |
2,248
+4.88%
|
-
|
|
Feb 20
2024
|
Jeffrey Thomas Elliott Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,112
+37.46%
|
-
|
|
Feb 15
2024
|
James Herriott SVP, General Counsel & Sec |
SELL
Open market or private sale
|
Direct |
421
-6.09%
|
$25,681
$61.43 P/Share
|
|
Feb 15
2024
|
Jacob A Orville EVP, GM, Screening |
SELL
Open market or private sale
|
Direct |
966
-11.43%
|
$58,926
$61.43 P/Share
|
|
Feb 15
2024
|
Sarah Condella EVP, Human Resources |
SELL
Open market or private sale
|
Direct |
965
-1.35%
|
$58,865
$61.43 P/Share
|
|
Feb 15
2024
|
Kevin T Conroy President and CEO |
SELL
Open market or private sale
|
Direct |
14,791
-1.19%
|
$902,251
$61.43 P/Share
|
|
Feb 15
2024
|
D Scott Coward |
SELL
Open market or private sale
|
Direct |
1,376
-3.2%
|
$83,936
$61.43 P/Share
|